Cipla Limited (CIPLA): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Cipla Limited, explained in plain English.
- Cipla Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- CIPLA closed at ₹1,417.00 on 18 November 2026.
- Over the past year the shares are down 6.4%, trading between ₹1,165.70 and ₹1,539.70.
- Reported fundamentals show return on equity of 8.33%, a net margin of 10.35%, debt to equity of 1.97.
- Our Pulse grade checklist scores it D (48/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
- Annualised volatility over the past year is 19.88% with a maximum drawdown of -22.13% and a beta of 0.51 against NIFTY 50.
- Recent coverage: Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%
Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma
Last traded values from 18 Nov 2026. Market closed.
Pharma & Healthcare · Drug Manufacturers - Specialty & Generic
Cipla Limited (CIPLA)
₹1,417
▲ 29 (+2.09%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Strong momentum · 4/51M
+6.94%
3M
-0.99%
6M
-0.65%
1Y
-6.44%
Where it sits in its 52-week range
66%Below 52-week high
7.5%
18.8% above the low
Momentum read
Strong
4/5 checks passed
52-wk high
₹1,531.3
52-wk low
₹1,192.4
Market cap
₹1,14,478 Cr
P/E (trailing)
39.5
Dividend yield
—
ROE
8.33%
Profit margin
10.35%
Revenue growth
-1.1%
Price / Book
3.23
Debt / Equity
1.97
EPS (TTM)
35.84
Book value
₹438.13
Beta
0.51
Pulse grade: D, 48 out of 100
Momentum
B- ✓Trading above 50-day average
- ✓Trading above 200-day average
- ✓RSI in healthy 45-70 zone
- ✕Positive 3-month return
Growth
D- ✕Revenue growth above Pharma & Healthcare median (20.8%)
- ✕Revenue growing above 5%
- ✓Quarterly profits trending up
Profitability
F- ✕Return on equity above Pharma & Healthcare median (14.64%)
- ✕Return on equity above 12%
- ✕Profit margin above Pharma & Healthcare median (13.82%)
Safety
A- ✓Debt below Pharma & Healthcare median (18.57)
- ✓Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹7,368 crore · net profit ₹878 crore · margin 11.9%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
| Peer | Price ₹ | Day change | From 52-wk high |
|---|---|---|---|
| SUNPHARMA | 1,871.5 | +0.08% | -6.48% |
| DRREDDY | 1,398.2 | +0.73% | 0.00% |
| DIVISLAB | 11,049 | -0.91% | -4.47% |
| APOLLOHOSP | 8,821 | +1.25% | -2.73% |
| LUPIN | 1,971.9 | +1.12% | -21.59% |
| AUROPHARMA | 1,796.3 | +0.12% | -3.18% |
CIPLA headlines
No CIPLA stories right now.
CIPLA filings & announcements
CIPLA, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
19.88%
Sharpe ratio
-0.55
Sortino ratio
-0.84
Max drawdown
-22.13%
Daily VaR (95%)
-1.53%
CAGR (1Y)
-6.29%
Return skew
1.38
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.